A compound according to formula: wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute -configuration; wherein R represents hydrogen or methyl; the ring represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X 1, X 2, X 3, and/or X 4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; Ar 2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10-membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, (C 3-6)cycloalkyl, halogen, cyano, (C 1-3)fluoroalkyl, (C 1-3)fluoroalkoxy, hydroxy, (C 1-4)alkoxy-(C 1-3)alkyl, hydroxy-(C 1-3)alkyl, -CO-(C 1-4)alkyl, and (C 3-6)cycloalkyl-oxy-; or Ar 2 represents a 2,3-dihydro-benzo[1,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1,3]dioxolyl group optionally di-substituted with fluoro; (R x) m represents one or two optional substituents independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, halogen, cyano, (C 1-3)fluoroalkyl, and (C 1-3)fluoroalkoxy; and Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, halogen, cyano, (C 1-3)fluoroalkyl, and (C 1-3)fluoroalkoxyl; with the exception of the compound (1,1'-biphenyl)-2-yl-{ -2-[3-(3-pyridinyl)-1 H -1,2,4-triazol-5-yl]-1-pyrrolidinyl}-methanone; or a pharmaceutically acceptable salt thereof. wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute -configuration; wherein R represents hydrogen or methyl; the ring represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X 1, X 2, X 3, and/or X 4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; Ar 2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10-membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, (C 3-6)cycloalkyl, halogen, cyano, (C 1-3)fluoroalkyl, (C 1-3)fluoroalkoxy, hydroxy, (C 1-4)alkoxy-(C 1-3)alkyl, hydroxy-(C 1-3)alkyl, -CO-(C 1-4)alkyl, and (C 3-6)cycloalkyl-oxy-; or Ar 2 represents a 2,3-dihydro-benzo[1,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1,3]dioxolyl group optionally di-substituted with fluoro; (R x) m represents one or two optional substituents independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, halogen, cyano, (C 1-3)fluoroalkyl, and (C 1-3)fluoroalkoxy; and Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4)alkyl, (C 1-4)alkoxy, halogen, cyano, (C 1-3)fluoroalkyl, and (C 1-3)fluoroalkoxyl; with the exception of the compound (1,1'-biphenyl)-2-yl-{ -2-[3-(3-pyridinyl)-1 H -1,2,4-triazol-5-yl]-1-pyrrolidinyl}-methanone;